New weapon targets Cancer's immune shields
NCT ID NCT05537740
Summary
This early-stage study is testing a new immunotherapy drug called BAY 3375968 for people with advanced solid tumors that have not responded to standard treatments. The drug aims to boost the immune system's ability to fight cancer by targeting specific cells that suppress immunity. Researchers will test the drug alone and combined with an existing immunotherapy (pembrolizumab) to find safe doses and see if it shows early signs of effectiveness against several cancer types.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Antwerp University Hospital | Oncology Department
Antwerp, 2650, Belgium
-
CHU de Liège
Liège, 4000, Belgium
-
Centre Oscar Lambret - Service Oncologie
Lille, 59000, France
-
Clinica Universidad de Navarra | Madrid | Oncologia
Madrid, 28027, Spain
-
Clinica Universidad de Navarra | Pamplona | Oncologia
Pamplona, Navarre, 31008, Spain
-
Ghent University Hospital | Drug Research Unit Department
Ghent, 9000, Belgium
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510000, China
-
Hospital Universitari Vall D Hebron | Oncologia Medica
Barcelona, 08035, Spain
-
Hospital Universitario Hm Sanchinarro | Oncologia Medica
Madrid, 28050, Spain
-
Institut Bergonie - Unicancer Nouvelle Aquitaine - Service Oncologie medicale
Bordeaux, 33000, France
-
Institut Gustave Roussy - Departement d'Innovation Therapeutique et d'Essais Precoces (DITEP)
Villejuif, 94805, France
-
Institut de Cancerologie Ouest - Saint Herblain - Oncologie medicale
Saint-Herblain, 44800, France
-
Jilin Cancer Hospital
Changchun, Jilin, 130000, China
-
LinYi Cancer Hospital (Linyi Tumor Hospital)
Linyi, 276001, China
-
National Cancer Center Singapore - Oncology Department
Singapore, 168583, Singapore
-
National University Hospital Medical Centre
Singapore, 119074, Singapore
-
OncoCare Cancer Centre | Gleneagles Medical Centre
Singapore, 258499, Singapore
-
Princess Margaret Cancer Centre - Oncology Department
Toronto, Ontario, M5G 2C4, Canada
-
Royal Marsden NHS Trust (Surrey)
Sutton, Surrey, SM2 5PT, United Kingdom
-
START | San Antonio
San Antonio, Texas, 78229, United States
-
South Texas Accelerated Research Therapeutics | START Rocky Mountain Region
West Valley City, Utah, 84119, United States
-
The Christie NHS Foundation Trust - Christie Hospital
Manchester, Greater Manchester, M204BX, United Kingdom
-
The Sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510655, China
-
The University of Chicago Medical Center - Hyde Park - Hematology & Oncology
Chicago, Illinois, 60637, United States
-
UNC Hospitals - UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27514, United States
-
Universitair Ziekenhuis Leuven | Gasthuisberg Campus - General Medical Oncology
Leuven, 3000, Belgium
Conditions
Explore the condition pages connected to this study.